Comparative efficacy of pharmacological interventions on mortality and mean length of hospital stay in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
This article was originally published here
Expert Rev Anti Infect Ther. October 25, 2021. doi: 10.1080 / 14787210.2022.1997587. Online ahead of print.
INTRODUCTION: So far, many randomized controlled trials (RCTs) have examined various drugs as possible treatments for coronavirus disease 2019 (COVID-19), but the results have been diverse and sometimes even inconsistent with each other. At this point, a decisive consensus on treatment is needed. Therefore, we performed a systematic review and meta-analysis (SR-MA) to assess the comparative efficacy of pharmacological agents in published RCTs.
AREAS COVERED: A literature search was carried out using the PubMed, SCOPUS, EMBASE and Web of Science databases. RCTs assessing mortality and mean length of hospital stay against standard of care (SOC) / placebo / control were included in our meta-analysis. RCTs have primarily been categorized into five drug categories, including anti-inflammatories, antivirals, antiparasitics, antibodies, and antibiotics. A meta-analysis was performed on 5 drug classes and a subgroup meta-analysis was performed on single drugs and in moderate or severe stage of the disease.
EXPERT OPINION: Mortality and average length of stay in COVID-19 patients were significantly reduced with anti-inflammatory drugs (odds ratio [OR]: 0.77, 95% confidence interval [CI]: 0.69 to 0.85, P